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Chou et al. discover a new mode of maternal inheritance by analyzing human mutations in plasma
retinol binding protein (RBP). Mechanistically, these mutations simultaneously lower RBP’s affinity
for vitamin A and greatly increase its affinity for its cell-surface receptor, thus dominantly blocking
the transmembrane transport of vitamin A.Vitamin A has been the light sensor for
vision, or its equivalent, from life’s begin-
nings. The diversification of its function
to regulating cell growth and differentia-
tion, which occurred about 500 million
years ago, coincided with the emer-
gence of a long-range and specific
vitamin A transport system consisting
of a blood carrier protein called plasma
retinol binding protein (RBP) and its
cell-surface receptor (STRA6), which
mediates vitamin A uptake (Kawaguchi
et al., 2007). Many organs depend on
vitamin A action; however, the eye is still
the organ most sensitive to vitamin A
deficiency, the loss of RBP, or the loss
of STRA6 (Zhong et al., 2012). Studies
of human mutations leading to con-
genital eye malformation allowed Tom
Glaser and colleagues, in this issue of
Cell, to uncover a new mode of maternal
inheritance and its intricate mechanism
involving RBP, STRA6, and vitamin A
(Chou et al., 2015).
Glaser’s team identified human RBP
mutations that cause eye malformation
such as anophthalmia, microphthalmia,
and coloboma, but the phenotypes are
preferentially transmitted if the muta-
tions are inherited from the mother.
Through a series of elegant biochemical
analyses, they discovered that these
mutant RBPs block vitamin A transport
by STRA6 in a precise and dominant
manner. To understand this mechanism,
it is useful to understand the major
players involved in specific vitamin A
transport. Under physiological condi-
tions, vitamin A/RBP complex (termed
holo-RBP) associates with transthyretin
(TTR) to increase its molecular weight
and thus prevent removal by kidney
filtration. Holo-RBP dissociates from thecomplex to bind to its cell-surface recep-
tor STRA6 due to its higher affinity for
STRA6 than for TTR (Kawaguchi et al.,
2011). STRA6 then catalyzes vitamin A
release from holo-RBP and its transport
into the cell where it is stored (Kawagu-
chi et al., 2011). After losing its cargo,
RBP (apo-RBP) has greatly decreased
affinity for TTR and is lost through kidney
filtration, which prevents its accumula-
tion in the blood (Figure 1). RBP muta-
tions identified in this study confer
several properties that are important for
their pathogenicity and the way they
affect this process. First, while these
mutant RBPs are as well secreted as
the wild-type protein, they bind vitamin
A weakly and tend to lose their cargo in
a receptor-independent manner. Sec-
ond, like wild-type holo-RBP, the mutant
ones can still bind to TTR; however, they
have an affinity for STRA6 that is 30- to
40-fold higher than that of wild-type
RBP (Figure 1). These properties lead to
the sequestration of STRA6 by the
mutant RBP, decreasing its ability to
transport vitamin A into the cell. Indeed,
although the blood of mutation carriers
may contain about 66% wild-type RBP
and only 33% mutant RBP, the blocking
effect is sufficient to cause the malforma-
tion phenotypes.
A longstanding puzzle in the field was
the discrepancy between the way human
mutations in RBP and STRA6 affect eye
development. While mutations in STRA6
cause anopththalmia and other develop-
mental defects (Pasutto et al., 2007), all
previously identified RBP mutations did
not. As this study shows, a key to this
puzzle is the placenta’s role in vitamin A
delivery. Previously identified mutations
in RBP were recessive and thus unlikelyCellto inactivate both maternal and fetal
RBP because only the fetus could be
homozygous for the mutation. In contrast,
dominant RBP mutations, like those
discovered in this study, can simulta-
neously inactivate the mother’s and fetal
RBP. Similarly, human mutations in RBP
and its receptor do not necessarily
generate the same phenotypes for the
same reason. A human embryo without
STRA6 can be directly impacted by the
loss of placental absorption of vitamin A
from maternal RBP. In contrast, a human
embryo without RBP still has STRA6
and functional maternal RBP to ensure
vitamin A delivery to the embryo through
the placenta. Thus, the dominant human
RBP mutations mimic STRA6 mutations
in their ability to inactivate both maternal
and fetal RBP-mediated transport and
therefore can cause anophthalmia. The
fact that the dominant RBP mutation can
only exert its effect on maternal delivery
of vitamin A to the fetus if it is maternal
explains this new mode of maternal
inheritance.
A related question highlighted by this
study is the contrast between humans
and mice in phenotypic variability even
for null mutations in this pathway. For
example, human pathologies caused by
STRA6 mutations are highly variable,
ranging from the ‘‘milder’’ phenotype
of anophthalmia to more systemic devel-
opmental defects (Pasutto et al., 2007).
However, under standard laboratory
conditions, STRA6 knockout mice, like
RBP knockout mice, have vision-specific
phenotypes that lead to blindness due to
lack of vitamin A (Amengual et al., 2014;
Ruiz et al., 2012). As pointed out here, a
key to this puzzle is an RBP-independent
pathway mediated by vitamin A esters161, April 23, 2015 ª2015 Elsevier Inc. 435
Figure 1. Schematic Diagrams of RBP/Receptor Interaction
Schematic diagrams comparing RBP/receptor interaction under physiological conditions and the pathological conditions revealed by Chou et al. (2015). Under
physiological conditions (left diagram), holo-RBP dissociates from the RBP/TTR complex to bind to the RBP receptor STRA6 due to its higher affinity for STRA6
than for TTR. STRA6 catalyzes retinol release from holo-RBP and retinol transport into the cell to be stored by binding to CRBP, or by conversion to retinyl esters
by LRAT (not shown). After losing its cargo retinol, RBP (apo-RBP) can no longer bind to TTR and is lost through kidney filtration. As depicted in the right diagram,
human RBP mutant A55T or A57T (marked in red in RBP structures) tends to lose vitamin A in a receptor-independent manner, but has much higher affinity for
STRA6 than wild-type RBP (themutant RBP/receptor complex is marked by a red circle). These RBPmutants compete with wild-type RBP in binding to STRA6 to
impede the transmembrane transport of vitamin A.(retinyl esters) borrowing the lipopro-
tein delivery pathway. This pathway can
partly compensate for the lack of RBP
if sufficient and constant vitamin A is
available (Quadro et al., 2005). Retinyl
ester bound to lipoprotein depends on
immediate vitamin A intake from food
because its source is the small intestine.
Unlike the RBP system, the retinyl ester
pathway is not homeostatically regu-
lated, cannot mobilize the vast amount
of vitamin A stored in the liver, and is
directly influenced by fluctuating vitamin
A intake (Green and Green, 1994). There-
fore, pathological phenotype becomes
highly variable and ranges from eye-spe-
cific pathology to embryonic lethality
when only this pathway is depended on
for vitamin A delivery in mice (Quadro
et al., 2005) or in humans (Pasutto
et al., 2007). Another facet of this RBP-
independent pathway is that it is associ-
ated with toxicity due to its lack of ho-436 Cell 161, April 23, 2015 ª2015 Elsevier Inmeostatic control and specificity (Smith
and Goodman, 1976). An increase of
10% in retinyl ester in the blood is re-
garded as a sign of vitamin A overload
in humans.
This study also illustrates how RPB
and its receptor have been finely tuned
for each other in evolution. Tighter bind-
ing is not necessarily better and can
even be pathogenic. Each RBP protein
transports only one vitamin A molecule
and STRA6 only takes up one vitamin A
molecule at a time from RBP. Therefore,
the STRA6/RBP interaction must be suf-
ficiently strong and specific to achieve
vitamin A uptake, but not too strong or
prolonged to prevent RBP from deliv-
ering the next vitamin A molecule. The
unexpected existence of super-binding
RBP mutants in humans revealed a
new mode of inheritance depending
on the genetic buildup of both mother
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